~~<i id='C5B152B489'><strike id='C5B152B489'><tt id='C5B152B489'><pre id='C5B152B489'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

leisure time

author：explore 2025-08-23 21:56:39 - browse：498

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： How generative AI ratchets up security threats for health systems

entertainment

knowledge

focus

explore

leisure time

RobertF.KennedyJr.arrivesinthelobbyofTrumpTowerinNewYorkforameetingwithPresident-electDonaldTrump.Ev

WSS

10 reasons why health care startups fail

Hilary may become 1st tropical storm to make landfall in California in 84 years

As Maui death toll rises, number of missing remains unclear

Beware the threat of staffing cuts at the CDC

Wegovy leads to weight loss. Can it treat depression, too?

Baltimore teen accused of firing into crowd during block party mass shooting

entertainment

leisure time

entertainment

Drug repurposing or repositioning? The language matters

The pain doctors face in trying to build their families

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Listen: Racing for gene therapy & a pioneering approval

Apple is now the first public company to be valued at $3 trillion

Medicare Advantage insurers face 0.2% cut to 2025 payments

Virginia high school admissions case could be legal follow

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Bright Health sells Medicare Advantage business to Molina

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

knowledge

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

The pain doctors face in trying to build their families

10 reasons why health care startups fail

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Congress must give Medicare recipients genetic counseling access

Syphilis numbers in the United States reach record heights

focus

focus

explore

leisure time